

Exercise testing to guide safe discharge from hospital in COVID-19: a scoping review to identify candidate tests

Rhys, Gwenllian; Wakeling, Tara; Moore, Jonathan; Subbe, Chris

BMJ Open

DOI:
[10.1136/bmjopen-2022-068169](https://doi.org/10.1136/bmjopen-2022-068169)

Published: 31/10/2023

Publisher's PDF, also known as Version of record

[Cyswllt i'r cyhoeddiad / Link to publication](#)

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Rhys, G., Wakeling, T., Moore, J., & Subbe, C. (2023). Exercise testing to guide safe discharge from hospital in COVID-19: a scoping review to identify candidate tests. *BMJ Open*, 13(10), Article e068169. Advance online publication. <https://doi.org/10.1136/bmjopen-2022-068169>

Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

BMJ Open Exercise testing to guide safe discharge from hospital in COVID-19: a scoping review to identify candidate tests

Gwenllian Haf Rhys ^{1,2}, Tara Wakeling,¹ Jonathan P Moore ²,
Christian Peter Subbe^{3,4}

To cite: Rhys GH, Wakeling T, Moore JP, *et al.* Exercise testing to guide safe discharge from hospital in COVID-19: a scoping review to identify candidate tests. *BMJ Open* 2023;**13**:e068169. doi:10.1136/bmjopen-2022-068169

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-068169>).

Received 16 September 2022
Accepted 20 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Medicine, Ysbyty Gwynedd, Bangor, UK

²School of Psychology and Sport Science, Bangor University, Bangor, UK

³Acute Medicine, Ysbyty Gwynedd, Bangor, UK

⁴North Wales Medical School, Bangor University, Bangor, UK

Correspondence to

Dr Jonathan P Moore;
j.p.moore@bangor.ac.uk

ABSTRACT

Objectives We aimed to identify exercise tests that have been validated to support a safe discharge to home in patients with or without COVID-19.

Study design Scoping review, using PRISMA-ScR reporting standards. Medline, PubMed, AMED, Embase, CINAHL and LitCovid databases were searched between 16 and 22 February 2021, with studies included from any publication date up to and including the search date.

Intervention Short exercise tests.

Primary outcome measures Safe discharge from hospital, readmission rate, length of hospital stay, mortality. Secondary outcomes measures: safety, feasibility and reliability.

Results Of 1612 original records screened, 19 studies were included in the analysis. These used a variety of exercise tests in patients with chronic obstructive pulmonary disease, suspected pulmonary embolism and pneumocystis carinii pneumonia, heart failure or critical illness. Only six studies had examined patients with COVID-19, of these two were still recruiting to evaluate the 1 min sit-to-stand test and the 40-steps test. There was heterogeneity in patient populations, tests used and outcome measures. Few exercise tests have been validated to support discharge decisions. There is currently no support for short exercise tests for triage of care in patients with COVID-19.

Conclusions Further research is needed to aid clinical decision-making at discharge from hospital.

BACKGROUND

Oxygen saturation is a key parameter in the Early Warning Score, a tool instrumental in identifying the physiological deterioration that frequently precedes clinical deterioration in patients.¹ With the emergence of COVID-19, the feature of silent hypoxaemia gained prominence, referring to patients with severely low oxygen levels, who do not exhibit corresponding features of respiratory distress.^{2 3} Understanding that patients at risk of deterioration from COVID-19 could exhibit hypoxaemia as an early indicator of future clinical deterioration,^{4 5} with or without the presence of dyspnoea, has led

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ First scoping review to comment on the evidence for using exercise testing within the acute assessment of COVID-19 cases.
- ⇒ Scoping review method following Preferred Reporting Items for Systematic Reviews and Meta-analysis extension for Scoping Reviews reporting guidelines, comprising an extensive search in Medline, PubMed, AMED, Embase, CINAHL and LitCovid databases.
- ⇒ Abstracts screened by two independent authors using predefined inclusion and exclusion criteria as outlined in our study protocol. The scoping review protocol allowed for any exercise test performed in an acute hospital or primary care setting, in acute cardiopulmonary disease including COVID-19, excluding acute coronary syndrome.
- ⇒ The review allowed for surrogate outcomes for safe discharge including length of hospitalisation, rehospitalisation, clinical deterioration and mortality.

to the integral role of oximetry in the assessment of suspected COVID-19.⁶

As well as silent hypoxia, there have been reports of patients presenting with COVID-19, who have normal oxygen saturation at rest, and develop hypoxaemia on exertion.⁷ This has led to the inclusion of exercise testing in guidance for the assessment of suspected COVID-19, within primary care and emergency departments (EDs).^{8 9} Emerging evidence of exertional hypoxaemia in COVID-19 as a potential indicator of future deterioration¹⁰ has increased interest in an appropriate exercise test within the acute setting to detect exertional desaturation.

Greenhalgh *et al* used a panel of front-line clinicians to gather consensus on a risk score for suspected COVID-19 in primary care, which includes a suggestion to perform the 40 steps desaturation tests in patients with oxygen saturations above 96%.¹¹ This test initially appeared in NHS England guidance for ED assessment during the first wave of

the pandemic in the UK,¹² but has not been validated, although it may closely resemble non-standardised walking tests commonplace in clinical practice.

There is an urgent need to identify an appropriate rapid exercise test for the acute setting to assess exertional desaturation in the unwell patient. The test needs to distinguish patients most at risk of deterioration, while ensuring those not desaturating are safe to recover from their illness at home.

This review aims to identify where exercise tests have previously been used in the clinical setting as a discharge decision aid, or way of escalating definitive diagnosis and management in COVID-19 and other acute cardiopulmonary disease.

The review questions for the purpose of this study include:

- ▶ Which exercise tests have been validated for use in the context of COVID-19?
- ▶ Which existing exercise tests have been used as part of patient assessment in the acute setting to promote safe discharge from hospital?
- ▶ Which exercise tests have been shown to effectively demonstrate exertional desaturation and can they be applied safely to an acute setting? What degree of desaturation during an exercise test is significant in acute lung disease, for outcomes including safe discharge, hospitalisation, mortality, length of stay?

METHODS

Study design

A scoping review format was used with a protocol designed with reference to the Preferred Reporting Items for Systematic Reviews and Meta-analysis extension for Scoping Reviews (PRISMA-ScR)¹³ reporting guidelines.

The Population, Intervention, Comparator and Outcome (PICO) question for the review was: ‘which exercise tests (I) can be used in the assessment of adults in acute care settings (P), in addition to usual care (C), to promote safe discharge from hospital (O)?’

Inclusion and exclusion criteria

Studies conducted in an ED, medical admissions unit, inpatient ward, intensive care unit (ICU), ambulance service and primary care were included. Adult patients presenting to acute settings with symptoms suggesting an acute coronary syndrome were excluded. ‘Exercise testing’ was defined as any walk, step, sit-to-stand, incremental shuttle, stair climb, bicycle ergometry or treadmill tests. Included were tests used at any part of an acute admission: on presentation (to identify the need for hospitalisation), during admission or at the time of discharge (to identify clinical stability to allow transfer to the community) as long as one of the primary or secondary outcome measures was included in the reporting. Any study publication date up to and including the search date was included in the analysis.

The primary outcome measure was safe discharge as defined by an absence of rehospitalisation or, mortality, length of hospital stay or need for further investigation.

Secondary outcomes included safety, feasibility and reliability of the test in the acute setting. Randomised control trials, cohort studies, case-control studies, observational studies, and systematic reviews were screened for references of any relevant studies that met the inclusion criteria outlined. Specific exclusions are outlined further in the study protocol (online supplemental file 1).

Information sources

Our structured search included the Medline, PubMed, AMED Embase, CINAHL and LitCovid electronic databases, and ClinicalTrials.gov and Clinical Trials registry (EU) for ongoing studies. The search terms used are outlined in online supplemental file 2. The titles and abstracts of the studies identified by the search were screened independently by two review authors using the Rayyan¹⁴ platform. Discrepancies were discussed between the two reviewers and, where necessary, a third independent reviewer was consulted. A full-text review of all included papers was then completed to confirm eligibility.

Data extraction was done by a single author. Assessment of the quality of research including risk of bias was not formally assessed within the scope of this review. The study selection was reported using the standards outlined in the PRISMA-ScR.¹³ The data included was analysed in relation to the review questions and outcomes outlined, discussing COVID-19 and other acute cardiopulmonary disease separately. The results are used to discuss suitable tests for assessing exertional desaturation in the acute setting, including needs for future research.

Patient and public involvement

Patients and the public were not consulted in the design of this research; however, the results have clear implications for patients and the public, and we would anticipate patient involvement in subsequent research and clinical policy decisions arising from the findings of this review.

RESULTS

In total, 1944 records were identified by the searches, of which 339 were duplicates. Of 1612 original records screened, 17 completed studies and 2 ongoing studies were included in the analysis stage (figure 1). The demographics of the studies are summarised in table 1. Studies were from the UK (1), Europe (7), North America (4), Asia (2), South America (1) and Australia (1). Multiple different outcomes and heterogeneity of methods and populations preclude a meta-analysis. Completion rates of the chosen exercise test varied from 32% to 100% (median 99%). The most used cut-offs were 3% desaturation and desaturating below 90% in four studies each.

COVID-19

Four studies included patients with confirmed or suspected COVID-19 (table 2). Two further studies were still recruiting (online supplemental file 3). Kamran *et al*¹⁵ assessed patients at admission for minimal desaturation,




Figure 1 Consolidated Standards of Reporting Trials flow diagram showing the study selection process. In total, 1944 records were identified by the search, 1612 abstracts were screened and 19 studies were included in the final evaluation (17 completed and 2 ongoing studies).

using a 10-foot desaturation test. The mean drop in oxygen saturation following the exercise test was 3% in stable patients, 9% in patients who clinically deteriorated ($p < 0.001$) and 15% in patients who later died ($p < 0.001$). Overall, 52% of patients who remained stable desaturated $\geq 3\%$, compared with 84% of the clinically deteriorating group and 96% of the mortality group (χ^2 square test, $p < 0.001$). However, on multivariate Cox regression analysis, desaturation during the 10-foot test was not a significant predictor of deterioration (HR 0.99, CI 0.95 to 1.04, $p = 0.706$).

Fuglebjerg *et al*¹⁶ screened 47 inpatients with COVID-19 with oxygen saturation (SpO_2) $> 94\%$ and no fever, recruiting 26 patients without comorbid lung or cardiac disease. Overall, 50% of the participants terminated

the 6 min walk test (6MWT) due to desaturation below SpO_2 90%, of whom 46% were admitted to ITU and 15% received mechanical ventilation. Only 46% of these cases were investigated further for pulmonary embolism (PE), but of those investigated, 67% tested positive for PE.

Banzi *et al*¹⁷ assessed the feasibility of a daily rapid walk test as an admission decision tool in primary care, using 5% desaturation to trigger admission. None of the 37 patients in the study met this threshold. One patient was admitted due to a $\text{SpO}_2 < 90\%$ at rest and required CPAP. Due to the small sample obtained conclusions about feasibility were not reached.

Goodacre *et al*¹⁰ retrospectively analysed 22 000 records, identifying 817 suspected or confirmed COVID-19 patients presenting to ED who had post-exertional oxygen

**Table 1** Demographics of included studies

| Reference | Study type | Setting | Diagnosis | Participants | Demographics |
|---|--|---|---|------------------------------------|--|
| Kamran <i>et al</i> ¹⁵ | Single-centre cross-sectional study | Hospital, Pakistan | COVID-19 | 252 | Age, median (range): 63 (29–85) Sex, %: male, 61.5 |
| Fuglebjerg <i>et al</i> ¹⁶ | Prospective cohort study, retrospective control group | Hospital, Denmark | Cases: COVID-19 controls: IPF | Cases: 26 Controls: 204 | Age, median (IQR): 59 (50–70) Sex, %: male 86.5 |
| Banzi <i>et al</i> ¹⁷ | Pilot feasibility study | Primary care, Italy | Suspected or confirmed COVID-19 | 37 | Age, median (range): 53.9 (23–83) Sex, %: male 27% |
| Goodacre <i>et al</i> ¹⁰ | Observational cohort study (mixed prospective and retrospective methodology) | Multicentre, ED, UK | Suspected or confirmed COVID-19 | 817 | Age, mean (SD): 58.4 (24.2) Sex, %: male, 49.2, female, 49.9, not recorded 0.9 Ethnicity, %: white 58.1, Asian 8.2, black 5.8, mixed/multiple 2.2, other 5.8, not recorded 20.0 |
| Danielsbacka <i>et al</i> ¹⁹ | Cross-sectional study | Medical admissions unit, Sweden | PE, subdivided into two groups based on vessel occlusion | 50 | Age, mean (SD): 54.7 (9.9) Sex, %: male, 39 |
| McCabe <i>et al</i> ²⁰ | Observational cohort study | Hospital, USA | Heart failure | 71 | Age, mean (SD): 52.6 (12.3) Sex, %: female, 42.3 Ethnicity, % |
| La Rovere <i>et al</i> ²¹ | Retrospective cohort study | Cardiology unit, Italy | Heart failure | 466 | Age, mean (SD): 61.3 (±11.0) Sex, %: male 35.0 |
| Sakai <i>et al</i> ²² | Prospective cohort study | Hospital, Japan | Interstitial pneumonia | 73 | Age, mean: 68.5 Sex, %: male 63 |
| Howie-Esquivel and Dracup ²³ | Prospective pilot Study | Hospital, USA | Heart failure | 44 | Age, mean (range): 59.6 (27–100) Sex, %: male 65.9 Ethnicity, %: Caucasian/white: 50 African American/black: 29.5, Hispanic/Latino: 11.4 Asian/Pacific Islander: 9.1 |
| Amin <i>et al</i> ²⁴ | Prospective cohort study | ED and rapid access thrombosis clinic, Canada | Suspected PE | 114 | Age, mean: 52.9 Sex, %: male 36.8 |
| Pan <i>et al</i> ²⁵ | Prospective cohort study | ED, Canada | CCF, COPD and stable chest pain | 40 | Age, mean (range): 69 (53–91) Sex, %: male, 60. |
| José and Dal Corso <i>et al</i> ²⁶ | Case-control study | Hospital, Brazil | Cases: acute lung disease Controls: healthy volunteers | Cases: 77 Controls: 20 | Age, mean: 56 (36–68) case, 52 (41–66) control Sex, %: male 59.7 |
| Kakavas <i>et al</i> ²⁷ | Observational cohort study | Pulmonary unit, Greece | AECOPD | 22 | Age, mean (SD): 67.2 (7.2) Sex, %: male, 63. |
| Chouaid <i>et al</i> ²⁸ | Prospective cohort study | Respiratory unit, France | HIV positive, suspected PCP | 85 | Age, median (range): 35 (25–60) Sex, %: male 90.5 |
| Sauleda <i>et al</i> ²⁹ | Case-control study | ED, Spain | HIV positive Cases: PCP Controls: non-PCP | Cases: 22 Controls: 23 | Age, mean (SE): cases 31 (1), controls 28 (1) |
| Kichura <i>et al</i> ³⁰ | Prospective cohort study | ED, USA | Heart failure | 50 | Age, median (SD): 66.2 (±12.5) Sex, %: male 42 |
| Denehy <i>et al</i> ³¹ | Nested cohort study | ICU, Australia | ICU inpatients | 144 at admission, 116 at discharge | Age, mean (SD): 60.4 (15.8) Sex, %: male, 63 |

AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; ED, emergency department; ICU, intensive care unit; IPF, idiopathic pulmonary fibrosis; PCP, pneumocystis pneumonia; PE, pulmonary embolism.

Table 2 Exercise testing in COVID-19

| Reference | Intervention | Physiological monitoring | Outcome |
|---------------------------------------|---|---|--|
| Kamran <i>et al</i> ¹⁵ | 10-foot walk O ₂ desaturation test at hospital admission | O ₂ saturations using pulse oximeter, supported by ABG—≥3% desaturation cut-off used | 128 stable, n (%): ▶ <3%: 62 (48.4) ▶ ≥3%: 66 (51.6) 124 clinical deterioration, n (%): ▶ <3%: 17 (13.7) ▶ ≥3%: 107 (86.3) (χ ² p<0.0001) 49 mortality, n(%): ▶ <3%: 2 (4.1) ▶ ≥3%: 47 (96.0) (χ ² p<0.0001) |
| Fuglebjerg <i>et al</i> ¹⁶ | 6MWT at hospital discharge | SpO ₂ using pulse oximeter—terminated early if below 90% | Early termination: 50% 46.2% of terminated tests investigated further. PE confirmed in 66.7% of those investigated further. |
| Banzi <i>et al</i> ¹⁷ | Daily rapid walk test as admission decision tool | SpO ₂ using pulse oximeter—desaturation≥5% or <90% used to trigger hospitalisation | 0% patients desaturated≥5%, 3% (1 patient) desaturated below 90%—hospitalised and required CPAP Insufficient sample size for feasibility conclusions |
| Goodacre <i>et al</i> ¹⁰ | Exertional test (not standardised) | SpO ₂ following exertion— not standardised— ≥3% desaturation considered significant | 30-day adverse outcomes: Multivariable primary analysis: ▶ c-statistic—0.59 (95% CI 0.465 to 0.713) ▶ PPV of ≥3% desaturation 1.78 (95% CI 1.25 to 2.53) ▶ 0.67 of ≥3% desaturation (95% CI 0.46 to 0.98) Multivariable model secondary* analysis: ▶ c-statistic—0.67 (0.46 to 0.98) ▶ PPV of ≥3% desaturation—1.98 (95% CI 1.26 to 3.10) ▶ NPV of ≥3% desaturation—0.61 (95% CI 0.35 to 1.07) |

*Excluded ages<16 years, SpO₂<94%, National Early Warning Score>3.¹⁸

ABG, arterial blood gas; CPAP, continuous positive airway pressure; c-stat, concordance statistic; CXR, X-ray of the chest; ITU, intensive treatment unit; 6MWT, 6 min walk test; NPV, negative predictive value; O₂, oxygen; PE, pulmonary embolism; PPV, positive predictive value; SpO₂, peripheral oxygen saturation.

saturations recorded. The exertional test used was not standardised. Mean decrease in oxygen saturation was 2.9% in the adverse outcome group (needing any cardiorespiratory, renal support or death) compared with 1.9% in the no adverse outcome group, with 3% desaturation found to be optimal at predicting adverse outcome. Exertional desaturation was not found to be predictive of adverse outcomes in the primary analysis cohort (p=0.376), but a secondary analysis cohort excluding participants with a baseline SpO₂<94%, National Early Warning Score¹⁸ of 3 or more, age below 16 years and limited ability to self-care, indicated that desaturation≥3% could be predictive of adverse outcomes in this group (p=0.019).

Other acute cardiopulmonary disease

Table 3 summarises findings in other acute cardiopulmonary disease. Five studies using a 6MWT alone were identified. A lower 6 min walk distance was linked to higher rates of vessel occlusion from pulmonary embolism,¹⁹ as well as rehospitalisation within 30 days,²⁰ and 12 months²¹ in heart failure patients. One study in interstitial pneumonia²² found 4% desaturation during the 6MWT to be optimal to predict rehospitalisation within 12 months from respiratory-related events (71% sensitivity, 79% specificity). The study also found the SpO₂ recovery index;

a measure of SpO₂ 1 min after the 6MWT, minus the lowest recorded SpO₂ at the end of the 6MWT, showed a significant association with rehospitalisation (HR 0.30 (95% CI 0.10 to 0.90), p=0.03). However, another study²³ conducted the 6MWT in 44 patients with heart failure 24–48 hours prior to discharge but found no association between the lowest SpO₂ value and 90-day cardiac-related rehospitalisation (HR 1.01, 95% CI 0.94 to 1.08, p=0.78).

The 3 min walk test (3MWT) was used in patients with suspected PE, using SpO₂<86% for 30 s, desaturation≥2% or heart rate>100 beats per minute (bpm) as stopping criteria.²⁴ Overall, 66% of participants met at least one of these criteria, of whom 32% tested positive for PE. Overall, 10% of the PE group met the criteria versus 2% of the non-PE group. An SpO₂ decrease of more than or equal to 2% and heart rate increase of more than 10 bpm was 100% sensitive but only 11.9% specific for PE. A feasibility study using the 3MWT as a clinical decision tool in acute dyspnoea found that 42% of those with a poor outcome were unable to complete the 3MWT, compared with 4% of those with a good outcome.²⁵ A study comparing the Chester step test (CST) and modified incremental step tests (MIST) with the 6MWT found correlation with number of steps completed and reduced

**Table 3** Studies of exercise testing in acute lung diseases other than COVID-19 in the acute setting

| Reference | Intervention | Physiological monitoring | Outcome |
|---|---|--|---|
| Danielsbacka <i>et al</i> ¹⁹ | 6MWT on the day of discharge | Masimo Rad V.5 pulse oximeter finger probe End-test SpO ₂ <90% cut-off used | Qanadli score for PE grading groups compared (QS2=higher degree of occlusion) Mean 6MWD (m): ▶ QS1 516±98.4 ▶ QS2 446±137.4 p=0.050 Desaturation<90%: ▶ QS1 16% ▶ QS2 17% |
| McCabe <i>et al</i> ²⁰ | 6MWT prior to discharge | 6MWD | 30-day rehospitalisation: ▶ Mean 6MWD (m) readmission; 536±434 ▶ Mean 6MWD (m) no readmission: 811±380 p=0.02 |
| La Rovere <i>et al</i> ²¹ | 6MWT at discharge | Distance walked (6MWD) measured (m) | Mortality: 6MWD (m), mean±SD; ▶ Alive 408.9±95.9 ▶ Deceased 311.1±102.2 p<0.0001 |
| Sakai <i>et al</i> ²² | 6MWT at discharge | Pulsox-M pulse oximeter 4% determined as optimal cut-off | 12 month rehospitalisation in interstitial pneumonia: SpO ₂ recovery index; ▶ 71.4% sensitivity ▶ 79.2% specificity Kaplan-Meier analysis comparing≥4% vs <4%; p<0.001 |
| Howie-Esquivel and Dracup ²³ | 6MWT, inpatients | 6MWD and lowest O ₂ recorded with Writox (Nonin Medical) pulse oximeter | 90-day cardiac rehospitalisation: Lowest O ₂ value; ▶ HR (95% CI): 1.01 (0.94 to 1.08) p=0.78 6MWD; ▶ HR (95% CI): 0.99 (0.99 to 1.00) p=0.06 |
| Amin <i>et al</i> ²⁴ | 3MWT during diagnostic workup | Criticare 504-DXP pulse oximeter Positive criteria: SpO ₂ <86% for 30s, or HR>110 (CCF), >120 (COPD) for 60s or new chest pain | 65.8% of tests positive criteria: ▶ 32% positive for PE 10% of PE vs 2% non-PE group met criteria SpO ₂ drop≥2% and HR increase>10 bpm ▶ 100% sensitivity (95% CI 88.7 to 100) for PE diagnosis ▶ 11.9% specificity (95% CI 6.6 to 21.0) for PE diagnosis |
| Pan <i>et al</i> ²⁵ | 3MWT prior to discharge | Nellcor Puritan Bennett (NPB-40) pulse oximeter Terminated if Borg score>7, chest pain, SpO ₂ <86% for 30s or HR>120 for 60s, or patient's request | Poor outcome* within 14-days: Walk test completed in full: ▶ Poor outcome 58% ▶ Good outcome 96% p<0.01 End-test SaO ₂ <90%: ▶ Poor outcome 25%, ▶ Good outcome 0% p<0.01 |
| José and Dal Corso ²⁶ | CST, MIST and next day 6MWT in inpatients | SpO ₂ measured using a 9500 Nonin pulse oximeter | Exercise-induced desaturation (Mean; 95% CI): CST (-2%; -6 to 0) MIST (-2%; -6 to -1) Length of stay: Number of steps during CST (r=-0.23, p=0.049) Number of steps during MIST (r=-0.23, p=0.042) |
| Kakavas <i>et al</i> ²⁷ | 30s and five-repetition sit-to-stand tests at discharge | Number of repetitions in 30s and duration to five repetitions | COPD exacerbation within 12 months: 30s-STs, mean repetition±SD ▶ Yes 11±3 ▶ No 18±8 (p=0.05) 5-STs, mean duration±SD ▶ Yes 14.2±3.3 ▶ No 10.1±3.1 (p=0.05) |

Continued

Table 3 Continued

| Reference | Intervention | Physiological monitoring | Outcome |
|------------------------------------|--|---|--|
| Chouaid <i>et al</i> ²⁸ | Treadmill exercise test—increasing 2 min constant speed steps (2, 4, 6 and 8 km/h) | SpO ₂ measured using finger pulse oximetry | 22% confirmed PCP on diagnostic testing. 3% desaturation: ▶ 100% sensitivity for PCP ▶ 70%–80%† specificity for PCP SpO ₂ <96%: ▶ 100% sensitivity for PCP ▶ 31% specificity for PCP |
| Sauleda <i>et al</i> ²⁹ | 2 min pedalling on stretcher bed (40 cycles/min) | SaO ₂ measured by Ohmeda 3740 pulse oximeter Positive if desaturation≥3% | Desaturation≥3%: ▶ 77% of PCP ▶ 9% non-PCP pneumonia SaO ₂ decrease, mean % (SE): ▶ PCP: –1% p<0.01 ▶ Non-PCP pneumonia+2% p<0.05 Sensitivity 77%, specificity 91% Mortality: ▶ 100% PCP cases desaturated≥3% |
| Kichura <i>et al</i> ³⁰ | 3 min bike ergometry distance at admission and discharge | Distance biked recorded in metres DeskCycle Exercise Bike Pedal Exerciser (3D Innovations) used | Length of stay: Admission; r=–0.11, p=0.46 Discharge; r=–0.03, p=0.85 30-day readmission: Admission; r=–0.03, p=0.85 Discharge; r=0.02, p=0.91 |
| Denehy <i>et al</i> ³¹ | PFIT* at admission and discharge, compared with TUG and 6MWT | Sit-to-stand assistance, marching on the spot (steps/min), shoulder flexion and knee extension strength | Discharge to home: ▶ PFIT, OR 1.20, p=0.01 Length of stay: ▶ Admission PFIT, B coefficient –2.13, p<0.001 28-day readmission ▶ Admission PFIT not correlated (data not presented) |

*Admission to hospital, the need for BiPAP, intubation, relapse, or death.
†With or without prophylactic pentamidine.
B, beta; bpm, beats per minute; CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; CST, Chester step test; HR, heart rate; HRR2, heart rate recovery within 2 min; ITU, intensive treatment unit; MIST, modified incremental step test; 6MWD, 6 min walk distance; 3MWT, 3 min walk test; 6MWT, 6 min walk test; PCP, pneumocystis pneumonia; PE, pulmonary embolism; PFIT, physical function ITU test; QS1, qanadli score group 1; QS2, qanadli score group 2; r, Pearson correlation coefficient; SaO₂, oxygen saturation of arterial oxygen; SpO₂, peripheral oxygen saturation; 30s-STs, 30 s sit-to-stand test; 5-STs, 5 repetition sit-to-stand test; TUG, Timed up and go test.

length of hospital stay (CST r=–0.23, p=0.049, MIST; r=–0.23, p=0.042). Mean desaturation was 2% on all three tests. The 6MWD was found to correlate with CST (r=0.590) and MIST (r=0.64), and no adverse events were recorded.²⁶

One study in acute exacerbations of chronic obstructive pulmonary disease (COPD)²⁷ included a 30 s sit-to-stand (30s-STs) and five repetition sit-to-stand test (5-STs) at discharge (2 hours apart). Patients who had further exacerbation of COPD within 12 months had a mean of 7 less repetitions of the 30s-STs compared those with no further exacerbations (p=0.05). Mean time to complete the 5-STs was also significantly longer in those who had further COPD exacerbation within 12 months (p=0.05). Heart rate and SpO₂ during the test were not found to be correlated with future exacerbations.

Chouaid *et al*²⁸ used a treadmill exercise test in the diagnostic workup of patients with HIV positive with suspected pneumocystis pneumonia (PCP). A 3% decrease in saturation during the test had 100% sensitivity for PCP and

70%–80% sensitivity, with exertional desaturation more specific for PCP than resting hypoxia.

Two studies using cycle ergometry were identified including a study in patients with HIV presenting with symptoms of pneumonia.²⁹ Twenty-two cases had confirmed PCP, 23 controls had other non-PCP pneumonias. Desaturation of ≥3%, was met in 77% of PCP cases, compared with 9% of non-PCP pneumonias. The mean decrease in SaO₂ was 88%–84% in the PCP group (p<0.01), compared with 91%–93% in the non-PCP group (p<0.05).

Kichura *et al*³⁰ used a 3 min bicycle ergometry in 50 heart failure patients presenting to ED at admission and discharge. No significant correlation between bike distance and length of hospital stay, readmission or mortality was found.

The final included study assessed inpatients at an ICU, who completed a physical function ITU test (PFIT) including a marching on the spot test, which was compared with the timed up and go test and the 6MWT.

Higher PFIT scores (ie, better function) were found to be significantly associated with discharge to home (OR 1.20, $p=0.01$) and reduced length of hospital stay (B coefficient -2.13 , $p<0.001$). However, admission PFIT was not significantly associated with 28-day readmission.³¹

DISCUSSION

Principal findings

This scoping review is the first to describe the use of different exercise tests in the assessment of confirmed or suspected COVID-19. Two of the larger studies in COVID-19 excluded a high proportion of the screened population, suggesting that the test may not be safe to perform in the normal hospitalised population. The utility of an exercise test in COVID-19 to predict early deterioration, using postexertional desaturation, may be limited to mobile, high-functioning patients with stable observations at rest.

Strengths and limitations

The search included tests used at any part of an acute admission: on presentation, during admission or at the time of discharge as long as one of the primary or secondary outcome measures was included in the reporting. By including exercise testing at various time-points during a patient's hospital journey we sought to identify suitable exercise tests which could be applied as a discharge decision tool. Inclusion of these studies has provided important insights into the safety and feasibility of exercise testing in the acute hospital setting, which are important for clinicians wishing to incorporate an exercise test as part of a discharge pathway. However, the inclusion of exercise tests performed at different points in the disease course, as well as in different settings (eg, ED vs primary care) are likely to produce variable outcomes, and therefore caution is advised in using their conclusions to estimate whether a discharge can be considered safe.

We found few results matching our inclusion criteria. We opted to exclude tests carried out in the outpatient setting, which limited the scope of literature assessed and may have led to overlooking a brief exercise test, that could be appropriate for use in COVID-19, but has not yet been tested in the acute setting. The identified literature is methodologically diverse, consisting mainly of small studies, with significant variation in the exercise test performed, condition studied and outcomes assessed. This makes drawing definitive conclusions more challenging. In addition to physiological monitoring using oxygen saturation, parameters such as the walking distance, repetitions or time taken to complete a predefined test were used in several studies: these likely measure frailty and comorbidity as well as cardiopulmonary function so may be less useful in the acute setting to predict short term outcomes, particularly in COVID-19. Some of the studies^{22 27} identified used longer-term

outcomes of up to 12 months that are less useful in the assessment of acute presentation with COVID-19.

Relation of findings to previous studies

The utility of exercise testing in the acute setting, particularly in terms of aiding with safe discharge, remains up for debate. A rapid systematic review on the safety and efficacy of rapid exercise tests for exertional desaturation in COVID-19 proposed the 1 min sit-to-stand test as warranting further investigation,⁷ and our study has identified that an ongoing prospective trial aims to explore its use in the assessment of COVID-19 patients to predict hospitalisation and adverse events. The 1 min sit-to-stand test is validated in a range of settings,³² including in the preoperative assessment for lung transplantation,³³ and may be more beneficial in demonstrating exertional desaturation. However, it has been noted to induce high cardiopulmonary stress and requires significant muscular strength to stand from sitting without support. This may make it unsuitable for use in a remote setting and not easy to achieve by many hospitalised patients, including the most frail. Additionally, we did not find extensive data to support the use of sit-to-stand tests in the acute setting.

New additions to the field of exercise testing such as the 10-foot desaturation test and 40-steps desaturation test are being used in COVID-19 without prior validation. Clinical practicalities favour a shorter test, although the evidence base for the longer 6MWT is more widely established. The shortest comparable test in published studies is the 10 m walk test (10MeWT), which involves walking as quickly as possible between two points on a flat surface measuring 10 m, with the time taken to complete the test recorded. Excellent intertest and test-retest reliability was found between the 10MeWT, and 6MWT in a cohort of dementia patients,³⁴ and the 15 m and 30 m variations of the 6MWT in stroke patients.³⁵ However, these tests have been used to measure gait speed, not desaturation.³⁶ We found no evidence of a similarly short walk test which linked desaturation to clinical deterioration or mortality. The 3MWT may offer a compromise to deliver a timely yet more highly validated test. Observations in paediatric studies indicate a quicker walking speed during the first minute of the 6MWT, as well as moderate reliability from 3 min onwards, a finding that warrants further investigation in adult patients with a range of mobility, before recommendation of a shorter walking test can be made.³⁷

Implications for clinical practice

Our findings appear to substantiate previous recommendations that a desaturation of 3% or more is significant.³⁸ Overall, 5% or more desaturation appears to be too high a threshold in a cohort of COVID-19 patients,¹⁷ while a threshold of 2% has only been used in combination with a change in heart rate to predict PE,²⁴ and not found to correlate with hospital length of stay in COPD exacerbations.²⁶ Meanwhile, a desaturation value between 3% and 4% appears to be the most useful in balancing sensitivity and specificity in many of the studies discussed.^{15 16 29} A

cut-off SpO₂ below 90% (representing 4% desaturation, as these studies also specified a baseline saturation of 94%) has also been used with some success both in patients infected with COVID-19¹⁴ and patients not infected with COVID-19.²⁵ However, given the high variability in exercise test length and intensity used, the most appropriate threshold would need to be decided on a test-by-test basis and is likely to vary according to the disease studied.

COVID-19 provides diverse physiological challenges with desaturation potentially caused by pneumonitis, thromboembolic disease or myocarditis. These different mechanisms might be difficult to differentiate by clinicians tasked with screening large cohorts of patients in the setting of a pandemic, but further research should address the combination of exercise testing with other biomarkers such as troponin, lactate dehydrogenase (LDH) or Brain Natriuretic Peptide (BNP) to gain better insights into both aetiology and risk profile. LDH has been used as a marker of severity of illness in COVID-19³⁹ and might describe vascular permeability or indeed myocardial strain⁴⁰ and could be explored further as a marker for safe discharge.

All tests discussed were found to be safe with none or few adverse events reported. We broadly suggest that brief tests of exertion, requiring no equipment and limited space, and therefore easy to perform remotely or in a hospital cubicle are most feasible to deliver, particularly in the context of COVID-19 pneumonitis where desaturation could be more marked in the acute phase. The drawback is that we have identified a lack of validation for the shorter exertional tests used commonly in clinical practice including the 40-steps desaturation test which is part of national guidance on the assessment of COVID-19. A shorter test may be less sensitive to detect desaturation but could have high specificity to detect COVID-19, or its complications, and a validation study to assess this is urgently indicated.

Unanswered questions for future research

We did not identify any studies within suspected COVID-19 in which different exercise test approaches were compared, or where an exertional test was part of an interventional pathway compared with usual care. This limits the recommendation of a validated test to be applied in the acute setting of assessing acute COVID-19.

Shorter tests are more practical in the acute setting, but are less validated in relation to facilitating safe discharge. One of these in widespread use is the 40-steps desaturation test, although variations in applying the test exist due to its lack of validated protocol. Since the completion of this scoping review, our group has published preliminary findings from using an on-the-spot variation of the 40-steps desaturation test in acute inpatients.⁴¹ We observed that the 40-steps desaturation test may not be feasible in a significant proportion of acute inpatients. We were unable to recruit sufficient patients with COVID-19 within this study, therefore, larger studies in COVID-19 specifically are still required to elicit the utility of the

40-steps test within COVID-19 inpatients. A 1 min sit-to-stand test may also be suitable, but is harder to achieve, and has also not been studied in the acute setting. We found some evidence to support the use of a 3MWT, which despite being relatively brief still requires space to deliver and may be hard to complete in full by acutely unwell patients.

We found little evidence for using desaturation as a clinical decision tool in acute conditions, including COVID-19. Desaturation of 2%–4% on exertion has been associated with adverse outcomes including clinical deterioration, rehospitalisation and mortality in several small studies. However, as the literature identified differs widely in the clinical setting and timing of the exercise in relation to the disease course, the presence of desaturation on exertion should not be used in isolation to inform a safe discharge. Further research is required with clinical practicalities favouring a shorter test. The 40-steps test, which is widely used in clinical practice but is not validated for use in COVID-19, requires further exploration.

Twitter Gwennlian Haf Rhys @Gwennlian_Rhys

Contributors GHR: protocol design including search design, abstract screening, data extraction and analysis, writing and editing the article for publication, and author acting as guarantor. TW: protocol design including search design, abstract screening and data extraction. JPM: overseeing protocol and study design, data analysis and editing the article for publication. CPS: overseeing protocol and study design, abstract screening, data analysis and editing the article for publication.

Funding Betsi Cadwaladr University Health Board, award/grant number NA.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Gwennlian Haf Rhys <http://orcid.org/0000-0003-2956-999X>

Jonathan P Moore <http://orcid.org/0000-0002-4244-8220>

REFERENCES

- 1 Subbe CP, Kruger M, Rutherford P, *et al*. Validation of a modified early warning score in medical admissions. *QJM* 2001;94:521–6.

- 2 Simonson TS, Baker TL, Banzett RB, *et al.* Silent hypoxaemia in COVID-19 patients. *J Physiol* 2021;599:1057–65.
- 3 Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. *Am J Respir Crit Care Med* 2020;202:356–60.
- 4 Teo J. Early detection of silent hypoxia in COVID-19 pneumonia using smartphone pulse oximetry. *J Med Syst* 2020;44:134.
- 5 Xie J, Covassin N, Fan Z, *et al.* Association between hypoxemia and mortality in patients with COVID-19. *Mayo Clin Proc* 2020;95:1138–47.
- 6 NICE. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community | guidance. Available: <https://www.nice.org.uk/guidance/ng165> [Accessed 12 Apr 2021].
- 7 Greenhalgh T, Javid B, Knight M, *et al.* What is the efficacy and safety of rapid exercise tests for exertional desaturation in COVID-19? - the centre for evidence-based medicine. The Centre for EBM; 2020. Available: <https://www.cebm.net/covid-19/what-is-the-efficacy-and-safety-of-rapid-exercise-tests-for-exertional-desaturation-in-covid-19/> [Accessed 12 Apr 2021].
- 8 NHS England. Pulse oximetry to detect early deterioration of patients with COVID-19 in primary and community care settings. 2021. Available: <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/06/C0445-remote-monitoring-in-primary-care-jan-2021-v1.1.pdf> [Accessed 13 Apr 2021].
- 9 Walsall Healthcare NHS trust. Emergency department COVID-19 adult management. 2020. Available: [https://www.rcem.ac.uk/docs/Local Guidance/Walsall ED covid guidelines.pdf](https://www.rcem.ac.uk/docs/Local%20Guidance/Walsall%20ED%20covid%20guidelines.pdf) [Accessed 13 Apr 2021].
- 10 Goodacre S, Thomas B, Lee E, *et al.* Post-exertion oxygen saturation as a prognostic factor for adverse outcome in patients attending the emergency department with suspected COVID-19: a substudy of the PRIEST observational cohort study. *Emerg Med J* 2021;38:88–93.
- 11 Greenhalgh T, Thompson P, Weiringa S, *et al.* What items should be included in an early warning score for remote assessment of suspected COVID-19? Qualitative and Delphi study. *BMJ Open* 2020;10:e042626.
- 12 NHS England. Clinical guide for the management of emergency department patients during the coronavirus pandemic. NICE; 2020.
- 13 Tricco AC, Lillie E, Zarin W, *et al.* PRISMA extension for scoping reviews (Prisma-SCR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
- 14 Ouzzani M, Hammady H, Fedorowicz Z, *et al.* Rayyan—a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210.
- 15 Kamran SM, Mirza Z-E-H, Moeed HA, *et al.* CALL score and RAS score as predictive models for Coronavirus disease 2019. *Cureus* 2020;12:e11368.
- 16 Fuglebjerg NJU, Jensen TO, Hoyer N, *et al.* Silent hypoxia in patients with SARS Cov-2 infection before hospital discharge. *Int J Infect Dis* 2020;99:100–1.
- 17 Banzi R, Sala L, Colmi A, *et al.* Feasibility and efficacy of home monitoring for patients with suspected or confirmed COVID-19. *Recenti Prog Med* 2020;111:584–92.
- 18 National early warning score (NEWS) 2. London RCP; 2017. Available: <https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2> [Accessed 12 May 2021].
- 19 Danielsbacka JS, Olsén MF, Hansson P-O, *et al.* Lung function, functional capacity, and respiratory symptoms at discharge from hospital in patients with acute pulmonary embolism: a cross-sectional study. *Physiother Theory Pract* 2018;34:194–201.
- 20 McCabe N, Butler J, Dunbar SB, *et al.* Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. *Heart Lung* 2017;46:287–92.
- 21 La Rovere MT, Maestri R, Caporotondi A, *et al.* Pre-discharge evaluation in heart failure – additive predictive value of the 6-minute walking test to clinical scores. *Circ J* 2015;79:1756–63.
- 22 Sakai Y, Yamamoto S, Hoshina M, *et al.* Using Spo2 recovery index after a 6-minute walk test to predict respiratory-related events in hospitalized patients with interstitial pneumonia. *Sci Rep* 2019;9:15226.
- 23 Howie-Esquivel J, Dracup K. Does oxygen saturation or distance walked predict rehospitalization in heart failure? *J Cardiovasc Nurs* 2008;23:349–56.
- 24 Amin Q, Perry JJ, Stiell IG, *et al.* Ambulatory vital signs in the workup of pulmonary embolism using a standardized 3-minute walk test. *Can J Emerg Med* 2015;17:270–8.
- 25 Pan AM, Stiell IG, Clement CM, *et al.* Feasibility of a structured 3-minute walk test as a clinical decision tool for patients presenting to the emergency department with acute dyspnoea. *Emerg Med J* 2009;26:278–82.
- 26 José A, Dal Corso S. Step tests are safe for assessing functional capacity in patients hospitalized with acute lung diseases. *J Cardiopulm Rehabil Prev* 2016;36:56–61.
- 27 Kakavas S, Papanikolaou A, Kompogiorgas S, *et al.* Sit-to-stand tests in patients hospitalised for chronic obstructive pulmonary disease exacerbation: association with pulmonary function tests and risk of future exacerbations. *Int J Ther Rehabil* 2020;27:1–11.
- 28 Chouaid C, Maillard D, Housset B, *et al.* Cost effectiveness of noninvasive oxygen saturation measurement during exercise for the diagnosis of pneumocystis carinii pneumonia. *Am Rev Respir Dis* 1993;147:1360–3.
- 29 Sauleda J, Gea J, Aran X, *et al.* Simplified exercise test for the initial differential diagnosis of pneumocystis carinii pneumonia in HIV antibody positive patients. *Thorax* 1994;49:112–4.
- 30 Kichura AB, Duderija E, Vidic A, *et al.* Does a brief functional assessment in the emergency department predict outcomes of patients admitted with heart failure? The FASTER-HF study. *Arch Cardiovasc Dis* 2020;113:766–71.
- 31 Denehy L, de Morton NA, Skinner EH, *et al.* A physical function test for use in the intensive care unit: validity, responsiveness, and predictive utility of the physical function ICU test (scored). *Phys Ther* 2013;93:1636–45.
- 32 Bohannon RW, Crouch R. 1-minute sit-to-stand test: systematic review of procedures, performance, and clinimetric properties. *J Cardiopulm Rehabil Prev* 2019;39:2–8.
- 33 Kohlbrenner D, Benden C, Radtke T. The 1-minute sit-to-stand test in lung transplant candidates: an alternative to the 6-minute walk test. *Respir Care* 2020;65:437–43.
- 34 Chan WLS, Pin TW. Reliability, validity and minimal detectable change of 2-minute walk test, 6-minute walk test and 10-meter walk test in frail older adults with dementia. *Exp Gerontol* 2019;115:9–18.
- 35 Cheng DK, Nelson M, Brooks D, *et al.* Validation of stroke-specific protocols for the 10-meter walk test and 6-minute walk test conducted using 15-meter and 30-meter walkways. *Top Stroke Rehabil* 2020;27:251–61.
- 36 Peters DM, Fritz SL, Krotish DE. Assessing the reliability and validity of a shorter walk test compared with the 10-meter walk test for measurements of gait speed in healthy, older adults. *J Geriatr Phys Ther* 2013;36:24–30.
- 37 Vill K, Ille L, Schroeder SA, *et al.* Six-minute walk test versus two-minute walk test in children with duchenne muscular dystrophy: is more time more information? *Eur J Paediatr Neurol* 2015;19:640–6.
- 38 Kalin A, Javid B, Knight M, *et al.* Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in COVID-19: a rapid systematic review. *Syst Rev* 2021;10:77.
- 39 Fialek B, Pruc M, Smereka J, *et al.* Diagnostic value of lactate dehydrogenase in COVID-19: a systematic review and meta-analysis. *Cardiol J* 2022;29:751–8.
- 40 Masumoto A, Kitai T, Matsumoto S, *et al.* Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases. *J Cardiol* 2022;79:501–8.
- 41 Rhys GH, Wakeling T, Moosavi SH, *et al.* Feasibility and accuracy of the 40-steps desaturation test to determine outcomes in a cohort of patients presenting to hospital with and without COVID-19. *Clin Med (Lond)* 2022;22:203–9.